Neuralgia

Abstract

Neuralgia — pain arising in the distribution of one or more nerves — is the clinical face of neuropathic pain, pain caused by a lesion or disease of the somatosensory nervous system rather than by ongoing tissue injury. Its defining paradox is that damage to the pain system produces more pain, not less: injured and degenerating afferents fire ectopically, the spinal cord and brain amplify the signal through central sensitization, and descending control is weakened. This article treats neuralgia as a problem in the psychophysiology of pain, organised around four frameworks — gate control, the peripheral generator, central sensitization, and the modern definition of pain — with three interactive demonstrations of the mechanisms and a survey of the MeSH-defined neuralgia subtypes.

Keywords: neuralgia, neuropathic pain, sensation

Neuralgia is one of the clearest cases in which pain and tissue damage come apart. A person feels a lancinating, burning, or electric pain running along the course of a nerve, yet the pain is driven not by any injury in the tissue where it is felt but by damage to the nerve that serves it (Colloca et al., 2017). That displacement is the signature of *neuropathic* pain, which the field now defines as pain caused by a lesion or disease of the somatosensory nervous system itself (Finnerup et al., 2016). Modern pain science treats pain as an experience the nervous system constructs from many inputs — peripheral signals, central excitability, descending control, expectation, and mood — rather than a readout of injury (Raja et al., 2020), and neuralgia is a condition in which that construction is driven by a fault in the pain-signalling apparatus, at both the injured peripheral nerve and the central pathways that process its input (Finnerup et al., 2021).

What Neuralgia Is

Neuralgia is pain that follows the anatomical distribution of a nerve, classically paroxysmal and often described as shooting, stabbing, burning, or electric. MeSH files the descriptor under both peripheral nervous system diseases and pain, and defines it as intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve. Clinically it is the presenting form of *neuropathic pain*, which the International Association for the Study of Pain and the neuropathic pain community define as pain caused by a lesion or disease of the somatosensory nervous system — a definition that deliberately locates the fault in the pain apparatus rather than in the tissue where the pain is felt (Finnerup et al., 2016). The distinction that matters most is between *nociceptive* pain, a proportionate warning signal of actual tissue damage, and *neuropathic* pain, in which the signalling system itself is damaged and generates pain without a corresponding injury (Colloca et al., 2017).

Because a nerve lesion cannot always be seen directly, the field grades neuralgia by how firmly that lesion can be demonstrated: *possible* on the basis of a plausible history and a matching pain distribution, *probable* when a sensory examination confirms the pattern, and *definite* when a confirmatory test — imaging, biopsy, or neurophysiology — objectively establishes the lesion (Finnerup et al., 2016). What makes neuralgia a topic in cognitive psychology rather than neurology alone is the same feature that long made it puzzling: the decoupling of the pain from any local tissue state. The International Association for the Study of Pain defines pain as *an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage* — a definition that refuses to make tissue damage necessary for pain (Raja et al., 2020). Neuralgia is almost a textbook instance: real, often disabling pain generated by dysfunction of the pain system itself. Table 1 sets out the four frameworks this article uses to explain how such pain arises.

Types of Neuralgia

MeSH classifies neuralgia under the broader descriptor *Peripheral Nervous System Diseases*, and also cross-files it under *Pain*, and lists several narrower descriptors beneath it. These subtypes are not competing theories of one disease but distinct clinical syndromes that share the neuropathic mechanism while differing in the nerve involved and the lesion that damages it — a MeSH indexing classification for retrieval, not a claim that the categories are mutually exclusive or jointly exhaustive. A single patient may satisfy more than one, and many neuralgias (trigeminal neuralgia among them) are indexed elsewhere in the tree. None of the subtypes below yet has its own article on this site; each is named here with a one-line gloss drawn from its MeSH scope.

Gate Control and the Modulation of Pain

The conceptual foundation for understanding pain as something more than a stimulus readout was laid in 1965, when Ronald Melzack and Patrick Wall proposed the *gate control theory of pain*. Their insight was that the transmission of nociceptive signals is regulated by a neural gate in the dorsal horn of the spinal cord, whose setting depends on the balance of activity across fibre types and on descending signals from the brain (Melzack & Wall, 1965). Activity in large-diameter fibres — the fibres that carry touch and pressure — tends to close the gate; nociceptive small-fibre activity opens it; and descending control from the brain can open or close it according to attention, expectation, and mood. Gate control did not survive intact in every detail, but its central claim — that pain is modulated before it is ever felt, by both competing input and top-down control — became the foundation of modern pain science.

Gate control explains a set of everyday observations about neuralgia. Rubbing a struck shin, the relief of transcutaneous electrical nerve stimulation, and the way distraction blunts pain all work because large-fibre input or descending control closes the gate on a fixed nociceptive drive. The theory equally explains how neuralgia can *worsen*: when a nerve lesion destroys the large myelinated fibres that normally hold the gate shut, or when chronic pain erodes descending inhibition, the same nociceptive drive is felt far more intensely because the brake has been released. The demonstration below lets the reader operate that gate, holding the nociceptive drive fixed while raising and lowering the modulation supplied by large-fibre input and descending control, and watching the perceived pain rise and fall.

The Peripheral Generator: Ectopic Discharge

Gate control describes how a pain signal is modulated, but neuralgia poses a prior question: where does the signal come from when there is no stimulus to detect? The answer is that the injured nerve itself becomes the generator. When a peripheral nerve is damaged, the injured and regenerating axons do not fall silent; they become hyperexcitable, accumulating sodium channels and discharging *ectopically* — firing spontaneously, without any stimulus, from the site of injury and from the dorsal root ganglion (Woolf & Mannion, 1999). Marshall Devor's work showed that this ectopic activity arises not only in nociceptive C-fibres but also in the large low-threshold A-beta afferents, which helps explain why light touch and vibration — normally innocuous — can trigger the paroxysmal pain of a neuralgia (Devor, 2009).

The paradox the peripheral-generator model resolves is why *losing* nerve fibres should produce *more* pain rather than numbness. A degenerating afferent population does not simply stop signalling; the surviving and injured axons become a source of spontaneous traffic, so the nerve generates a steady pain signal from within. This is the mechanism of the constant, stimulus-independent burning and the shocks of an established neuralgia — a maladaptive response in which the nervous system's own plasticity, useful after most injuries, instead entrenches the pain (Costigan et al., 2009). The demonstration below models this counterintuitive relationship, letting the reader increase the degree of nerve injury and watch the rate of spontaneous ectopic firing — and the pain it produces — climb as the nerve is progressively damaged.

Central Sensitization and Descending Control

A peripheral generator explains where the abnormal signal starts, but not why the pain is so often out of proportion to it, or why it spreads beyond the territory of the injured nerve. For that, neuralgia recruits the central mechanisms common to chronic pain. Clifford Woolf showed that sustained nociceptive input increases the excitability of neurons in the central nervous system, so that the pain system amplifies its own signals — responding more strongly to a given input and beginning to respond to inputs that were previously innocuous (Woolf, 2011). This *central sensitization* produces *hyperalgesia*, in which mild noxious stimuli are felt as intensely painful, and *allodynia*, in which normally non-painful contact becomes painful; both are cardinal features of an established neuralgia.

The central changes compound with a weakening of the brain's *descending inhibition* — the top-down control that normally damps nociceptive transmission. As a hyperexcitable periphery drives a sensitizing centre whose inhibitory brake is failing, the gain of the whole system is turned up (Costigan et al., 2009). This is why neuralgia can decouple from the original lesion, spreading into neighbouring dermatomes, persisting long after any tissue has healed, and being triggered by the gentlest touch. It is also why the mechanism-based approach to neuropathic pain, championed by Ralf Baron, tries to read a patient's sensory profile — which combination of loss, ectopic firing, and sensitization dominates — rather than treating every neuralgia as one disease (Baron et al., 2010). The demonstration below plots perceived pain against stimulus intensity and lets the reader raise the degree of central sensitization, watching the response curve steepen and shift left until innocuous stimulation crosses into pain.

Figure 1

From Nerve Lesion to Perceived Pain in Neuralgia

Worked Example

The gate-control demonstration reduces the modulation of pain to a single transparent computation, worth working through because it shows how neuralgic pain can grow with no change in the peripheral drive. Let the nociceptive drive from the injured nerve be a fixed *D* on a 0-to-10 scale, and let the modulation *M* — the combined gate-closing effect of large-fibre input and descending inhibition, also on a 0-to-10 scale — reduce the pain in proportion to its strength. Model the perceived pain as *P = D* × [1 − *M* / 10], with the bracket clamped so that it never falls below zero: perceived pain is the nociceptive drive scaled down by how much modulation the system supplies.

Take a modest ectopic drive of *D* = 8. In a healthy nerve with intact large fibres and strong descending control — say *M* = 7 — the bracket is (1 − 7/10) = 0.3, and the perceived pain is 8 × 0.3 = 2.4, tolerable. Now suppose the lesion has destroyed the large myelinated fibres and chronic pain has eroded descending inhibition, so modulation falls to *M* = 2. The bracket rises to (1 − 2/10) = 0.8, and the perceived pain climbs to 8 × 0.8 = 6.4 — more than a twofold increase with *no change whatever* in the drive from the nerve. The arithmetic is illustrative rather than a measurement, but it captures the core claim of gate control: neuralgic pain can be released by the loss of a modulating brake, so that the destruction of large fibres is a mechanism of the pain and not merely a marker of nerve damage (Melzack & Wall, 1965; Devor, 2009).

Discussion

Neuralgia rewards the shift from a structural to a psychophysiological account because the structural account, on its own, misleads: the tissue where the pain is felt is often normal, and the fault lies in the nerve serving it and in the central pathways that process its input. What replaced the old view of unexplained nerve pain as mysterious or exaggerated was not a retreat into psychology but a more precise neurology — a demonstrable peripheral generator of ectopic discharge, measurable central sensitization, and a gradeable nerve lesion (Woolf & Mannion, 1999; Finnerup et al., 2016). The reframing matters for treatment. Because the lesion is in the nervous system, neuralgia responds poorly to conventional analgesics and instead to agents that damp neural excitability or restore inhibition — anticonvulsants, tricyclic and serotonin-noradrenaline antidepressants, and topical agents — whose evidence base a large systematic review and meta-analysis consolidated into modern first-line recommendations (Finnerup et al., 2015).

The mature account also explains why neuralgia is so heterogeneous. Trigeminal neuralgia, with its lightning paroxysms triggered by touch and its frequent origin in vascular compression of the nerve root, behaves and responds differently from the steady burning of a postherpetic or diabetic neuralgia (Cruccu et al., 2020; Maarbjerg et al., 2017). What unites them is the neuropathic mechanism; what distinguishes them is which part of that mechanism dominates. This is the logic behind mechanism-based stratification: rather than treating a diagnostic label, clinicians increasingly try to identify a patient's *sensory phenotype* — the particular mix of sensory loss, ectopic firing, and sensitization — and match treatment to it (Baron et al., 2010). Assessment tools built for this purpose, such as the Leeds Assessment of Neuropathic Symptoms and Signs, translate the presence of neuropathic mechanisms into a bedside score (Bennett, 2001).

Current Directions

The most consequential recent development is the consolidation of definition and grading. The updated neuropathic pain grading system gave the field an operational way to move from a suspected to a definite nerve lesion, ending years in which 'neuropathic' was applied inconsistently and studied under incompatible criteria (Finnerup et al., 2016). In parallel, the revised IASP definition of pain reset the conceptual baseline for how a pain such as neuralgia — real, disabling, and often without visible local damage — is understood and legitimised (Raja et al., 2020), and a comprehensive disease-primer synthesis brought the peripheral and central mechanisms into a single framework (Colloca et al., 2017).

The mechanistic frontier is the move from diagnosis to prediction. A synthesis of mechanisms and treatment argues that the future of neuralgia care lies in matching therapy to the mechanism generating a given patient's pain rather than to its anatomical label, using quantitative sensory testing and sensory phenotyping to assign patients to mechanism-defined subgroups (Finnerup et al., 2021). The same logic is reshaping trigeminal neuralgia, where imaging of neurovascular compression and the distinction between classical, secondary, and idiopathic forms are refining who benefits from which intervention (Cruccu et al., 2020). Across the field the direction is the same: from a static diagnosis toward mechanism-based, individualised prediction of what will relieve a particular neuralgia.

Common Misconceptions

If the painful area looks normal, the pain is not real.

Pain and visible tissue damage are decoupled. Neuralgia is a genuine disorder in which a lesion of the nerve, not the tissue where the pain is felt, generates the signal (Colloca et al., 2017), and the IASP definition explicitly separates pain from tissue damage (Raja et al., 2020).

Damaging a nerve should make the area numb, not painful.

Injured axons do not merely fall silent; they become hyperexcitable and fire ectopically, generating a stimulus-independent pain signal from within the nerve (Woolf & Mannion, 1999; Devor, 2009). Central sensitization then amplifies that signal (Woolf, 2011).

Ordinary painkillers should work for neuralgia.

Because the fault is in the nervous system rather than in inflamed tissue, neuralgia responds poorly to conventional analgesics and instead to drugs that reduce neural excitability, such as anticonvulsants and certain antidepressants (Finnerup et al., 2015).

Glossary

Allodynia.

Pain evoked by a stimulus that is not normally painful, such as light touch or a cool breeze; a hallmark of central sensitization in neuralgia.

Central sensitization.

An activity-dependent increase in the excitability of central pain neurons, so that the nervous system amplifies pain and responds to previously innocuous inputs.

Descending modulation.

Top-down control of nociceptive transmission by signals from the brain, which can open or close the spinal pain gate; its weakening amplifies neuralgic pain.

Dorsal horn.

The sensory grey matter of the spinal cord where primary afferents synapse and where the pain gate and much of central sensitization are located.

Ectopic discharge.

Spontaneous, stimulus-independent firing of injured or hyperexcitable nerve fibres; the peripheral generator of the constant pain of an established neuralgia.

Gate control theory.

Melzack and Wall's theory that a spinal gate regulates nociceptive transmission, closed by large-fibre input and modulated by descending control from the brain.

Hyperalgesia.

An increased pain response to a stimulus that is normally painful; an amplification of pain associated with central sensitization.

Neuropathic pain.

Pain caused by a lesion or disease of the somatosensory nervous system; neuralgia is its clinical expression in the distribution of a nerve.

Nociception.

The neural encoding and transmission of noxious stimuli; an input to the pain system, distinct from the conscious experience of pain.

Nociceptive pain.

Pain arising from actual or threatened damage to non-neural tissue and due to activation of nociceptors; the proportionate warning pain that neuropathic pain is contrasted with.

Pain.

An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage (IASP); an experience the nervous system constructs.

Postherpetic neuralgia.

A neuralgia that persists after a herpes zoster (shingles) infection, in which nerve damage from the reactivated virus leaves a chronic pain in the affected dermatome.

Sensory phenotype.

The individual pattern of sensory loss and gain — numbness, ectopic firing, allodynia — used to stratify neuropathic pain by mechanism rather than by diagnostic label.

Trigeminal neuralgia.

A paroxysmal facial neuralgia of the trigeminal nerve, classically triggered by light touch and often caused by vascular compression of the nerve root.

Key Researchers

Ralf Baron (University Hospital Schleswig-Holstein, Kiel). Neurologist who developed the mechanism-based, sensory-phenotyping approach to neuropathic pain, arguing that treatment should target the mechanism generating a patient's pain rather than its diagnostic label. Faculty Page

Nanna Brix Finnerup (ORCID 0000-0001-5541-0240). Neurologist at the Danish Pain Research Center, Aarhus University, who leads the current neuropathic-pain grading system and the pharmacotherapy meta-analyses that define first-line treatment. ORCID - Google Scholar

Ronald Melzack (1929-2019). Canadian psychologist at McGill University who, with Patrick Wall, proposed the gate control theory of pain and authored the McGill Pain Questionnaire, founding the modern psychology of pain. Wikipedia - Wikidata

Patrick David Wall (1925-2001). British neuroscientist at University College London who, with Ronald Melzack, co-authored the gate control theory and shaped the field's understanding of how the nervous system modulates pain. Wikipedia - Wikidata

Clifford J. Woolf (ORCID 0000-0002-6636-3897). Neurobiologist at Harvard Medical School who originated the concept of central sensitization, showing that the pain system amplifies its own signals and reshaping the mechanistic account of neuropathic pain. ORCID - Google Scholar

Frequently Asked Questions

What is neuralgia? Neuralgia is pain that runs along the distribution of one or more nerves, typically shooting, burning, or electric. It is the clinical expression of neuropathic pain, caused by a lesion or disease of the somatosensory nervous system (Finnerup et al., 2016; Colloca et al., 2017).

Is neuralgia the same as neuropathic pain? They are closely related. Neuropathic pain is the broad mechanism (pain from a lesion or disease of the somatosensory nervous system), and neuralgia is its presentation as pain in the territory of a specific nerve (Finnerup et al., 2016).

Why does damaging a nerve cause pain rather than numbness? Injured nerve fibres do not simply go quiet; they become hyperexcitable and fire spontaneously, a process called ectopic discharge, so the nerve generates a pain signal from within even with no stimulus (Woolf & Mannion, 1999; Devor, 2009).

Why does light touch sometimes trigger severe pain? In central sensitization the pain system becomes so excitable that inputs from large touch fibres, which normally signal only light contact, are read as painful. This is allodynia, a cardinal feature of an established neuralgia (Woolf, 2011).

What are the main types of neuralgia? MeSH lists several, including causalgia, Morton neuroma, postherpetic neuralgia, piriformis muscle syndrome, pudendal neuralgia, and sciatica. Trigeminal neuralgia is another common form indexed separately. They share the neuropathic mechanism but differ in the nerve and lesion involved.

Why do ordinary painkillers often fail? Because the fault lies in the nervous system rather than in inflamed tissue, neuralgia responds poorly to conventional analgesics. First-line treatment uses drugs that reduce neural excitability, such as anticonvulsants and certain antidepressants (Finnerup et al., 2015).

What is central sensitization? An activity-dependent increase in the excitability of central pain neurons that amplifies pain and causes the system to respond to normally innocuous inputs, producing hyperalgesia and allodynia and helping pain persist and spread (Woolf, 2011; Costigan et al., 2009).

How is neuralgia diagnosed? Clinicians grade the certainty of a nerve lesion from possible to probable to definite, using the history, a sensory examination, and confirmatory tests, and bedside tools such as the LANSS score help identify neuropathic mechanisms (Finnerup et al., 2016; Bennett, 2001).

References